Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial
Scott D. Solomon,John W. Ostrominski,Muthiah Vaduganathan,Brian Claggett,Pardeep S. Jhund,Akshay S. Desai,Carolyn S.P. Lam,Bertram Pitt,Michele Senni,Sanjiv J. Shah,Adriaan A. Voors,Faiez Zannad,Imran Zainal Abidin,Marco Antonio Alcocer‐Gamba,John J. Atherton,Johann Bauersachs,Chang‐Sheng Ma,Chern‐En Chiang,Ovidiu Chioncel,Vijay Chopra,Josep Comin‐Colet,Gerasimos Filippatos,Cândida Fonseca,Grzegorz Gajos,Sorel Goland,Eva Goncalvesová,Seok‐Min Kang,Tzvetana Katova,Mikhail N. Kosiborod,Gustavs Latkovskis,Alex Pui‐Wai Lee,Gerard C.M. Linssen,Guillermo Llamas‐Esperón,Vyacheslav Mareev,Felipe A. Martinez,Vojtěch Melenovský,Béla Merkely,Savina Nodari,Mark C. Petrie,Clara Inés Saldarriaga,Jose Francisco Kerr Saraiva,Naoki Sato,Morten Schou,Kavita Sharma,Richard Troughton,Jacob A. Udell,Heikki Ukkonen,Orly Vardeny,Subodh Verma,Dirk von Lewinski,Leonid G. Voronkov,Mehmet Birhan Yilmaz,Shelley Zieroth,James Lay‐Flurrie,Ilse van Gameren,Flaviana Amarante,Prabhakar Viswanathan,John J.V. McMurray
DOI: https://doi.org/10.1002/ejhf.3266
2024-05-13
European Journal of Heart Failure
Abstract:Baseline characteristics of FINEARTS‐HF participants. BMI, body mass index; CKM, cardiovascular‐kidney‐metabolic; eGFR, estimated glomerular filtration rate; FINEARTS‐HF, Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure; HF, heart failure; HFimpEF, heart failure with improved ejection fraction; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; KCCQ‐TSS, Kansas City Cardiomyopathy Questionnaire total symptom score; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; T2D, type 2 diabetes; UACR, urine albumin‐to‐creatinine ratio. Aims To describe the baseline characteristics of participants in the FINEARTS‐HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS‐HF trial is comparing the effects of the non‐steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF/HFpEF. Methods and results Patients with symptomatic HF, left ventricular ejection fraction (LVEF) ≥40%, estimated glomerular filtration rate ≥ 25 ml/min/1.73 m2, elevated natriuretic peptide levels and evidence of structural heart disease were enrolled and randomized to finerenone titrated to a maximum of 40 mg once daily or matching placebo. We validly randomized 6001 patients to finerenone or placebo (mean age 72 ± 10 years, 46% women). The majority were New York Heart Association functional class II (69%). The baseline mean LVEF was 53 ± 8% (range 34–84%); 36% of participants had a LVEF <50% and 64% had a LVEF ≥50%. The median N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) was 1041 (interquartile range 449–1946) pg/ml. A total of 1219 (20%) patients were enrolled during or within 7 days of a worsening HF event, and 3247 (54%) patients were enrolled within 3 months of a worsening HF event. Compared with prior large‐scale HFmrEF/HFpEF trials, FINEARTS‐HF participants were more likely to have recent (within 6 months) HF hospitalization and greater symptoms and functional limitations. Further, concomitant medications included a larger percentage of sodium–glucose cotransporter 2 inhibitors and angiotensin receptor–neprilysin inhibitors than previous trials. Conclusions FINEARTS‐HF has enrolled a broad range of high‐risk patients with HFmrEF and HFpEF. The trial will determine the safety and efficacy of finerenone in this population.
cardiac & cardiovascular systems